Adrienne Monson – Lifestyle
Author:
George Medicines
George Medicines: New England Journal of Medicine publishes global stroke outcomes trial that demonstrated reduction of risk for recurrent stroke by almost 40% with GMRx2 in patients with previous intracerebral hemorrhage
April 22, 2026
George Medicines extends global commercialization of GMRx2 into Australia and New Zealand with Arrotex licensing agreement
March 16, 2026
George Medicines signs exclusive licensing agreement with Ahngook Pharmaceutical to commercialize GMRx2 in Korea
March 11, 2026